공고 • Jun 30
Daan Gene Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Daan Gene Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (6 non-independent directors). Independent Director Jianbing Fan was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공고 • Apr 28
Daan Gene Co., Ltd., Annual General Meeting, May 19, 2026 Daan Gene Co., Ltd., Annual General Meeting, May 19, 2026, at 14:30 China Standard Time. Location: 1F, No. 19, Xiangshan Road, Science City, High-tech Development Zone, Guangzhou, Guangdong China 공고 • Mar 31
Daan Gene Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Daan Gene Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 공고 • Dec 31
Daan Gene Co., Ltd. to Report Fiscal Year 2025 Results on Apr 03, 2026 Daan Gene Co., Ltd. announced that they will report fiscal year 2025 results on Apr 03, 2026 공고 • Sep 30
Daan Gene Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Daan Gene Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 공고 • Jul 02
Daan Gene Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Daan Gene Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 공고 • Mar 31
Daan Gene Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Daan Gene Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 공고 • Mar 29
Daan Gene Co., Ltd., Annual General Meeting, Apr 18, 2025 Daan Gene Co., Ltd., Annual General Meeting, Apr 18, 2025, at 14:30 China Standard Time. Location: 1F, No. 19, Xiangshan Road, Science City, High-tech Development Zone, Guangzhou, Guangdong China 공고 • Dec 31
Daan Gene Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Daan Gene Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.035 loss in 3Q 2023) Third quarter 2024 results: CN¥0.076 loss per share (further deteriorated from CN¥0.035 loss in 3Q 2023). Revenue: CN¥190.7m (down 38% from 3Q 2023). Net loss: CN¥103.5m (loss widened 106% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance. 공고 • Sep 30
Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Daan Gene Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 31
Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023) Second quarter 2024 results: CN¥0.025 loss per share (down from CN¥0.27 profit in 2Q 2023). Revenue: CN¥202.1m (up 3.5% from 2Q 2023). Net loss: CN¥35.9m (down 110% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. New Risk • Aug 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. 공고 • Jun 29
Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Daan Gene Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Declared Dividend • Jun 08
Dividend reduced to CN¥0.015 Dividend of CN¥0.015 is 99% lower than last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 0.2%, which is lower than the industry average of 1.6%. 공고 • Jun 08
Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024 Daan Gene Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.15000000 on A shares for the year 2023. Record date is 13 June 2024. Ex-date is 14 June 2024. Payment date is 14 June 2024. Reported Earnings • May 01
First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023) First quarter 2024 results: CN¥0.26 loss per share (down from CN¥0.026 profit in 1Q 2023). Revenue: CN¥198.3m (down 42% from 1Q 2023). Net loss: CN¥363.3m (down CN¥399.9m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 36% per year whereas the company’s share price has fallen by 31% per year. Reported Earnings • Mar 31
Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022) Full year 2023 results: EPS: CN¥0.075 (down from CN¥3.86 in FY 2022). Revenue: CN¥1.18b (down 90% from FY 2022). Net income: CN¥104.7m (down 98% from FY 2022). Profit margin: 8.9% (down from 45% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Mar 04
Now 21% overvalued Over the last 90 days, the stock has fallen 14% to CN¥8.95. The fair value is estimated to be CN¥7.42, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 6.1%. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥7.29, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 32x in the Biotechs industry in China. Total loss to shareholders of 55% over the past three years. Buy Or Sell Opportunity • Jan 25
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to CN¥8.69. The fair value is estimated to be CN¥7.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 6.1%. 공고 • Dec 29
Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Daan Gene Co., Ltd. announced that they will report fiscal year 2023 results on Mar 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022) Third quarter 2023 results: CN¥0.035 loss per share (down from CN¥0.94 profit in 3Q 2022). Revenue: CN¥306.1m (down 89% from 3Q 2022). Net loss: CN¥50.2m (down 104% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. 공고 • Sep 30
Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023 Daan Gene Co., Ltd. announced that they will report Q3, 2023 results on Oct 31, 2023 New Risk • Aug 02
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 110% Cash payout ratio: 176% Dividend yield: 18% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 110% Cash payout ratio: 176% Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Reported Earnings • Aug 01
Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.26 (down from CN¥1.36 in 2Q 2022). Revenue: CN¥195.2m (down 94% from 2Q 2022). Net income: CN¥370.3m (down 81% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Board Change • Jul 28
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Deputy GM, Secretary & Director Bin Zhang is the most experienced director on the board, commencing their role in 2019. Independent Director Richard Zhu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. New Risk • Jun 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Dividend is not well covered by cash flows (176% cash payout ratio). Share price has been volatile over the past 3 months (6.8% average weekly change). Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥10.32, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years. 공고 • Jun 07
Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023 Daan Gene Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 17.50000000 on A shares for the year 2022. Record date is June 12, 2023. Ex-date is June 13, 2023. Payment date is June 13, 2023. Valuation Update With 7 Day Price Move • May 05
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥12.75, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 44x in the Biotechs industry in China. Total returns to shareholders of 6.2% over the past three years. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021) Full year 2022 results: EPS: CN¥3.95 (up from CN¥2.58 in FY 2021). Revenue: CN¥12.0b (up 56% from FY 2021). Net income: CN¥5.54b (up 53% from FY 2021). Profit margin: 46% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.94 (up from CN¥0.66 in 3Q 2021). Revenue: CN¥2.66b (up 24% from 3Q 2021). Net income: CN¥1.32b (up 42% from 3Q 2021). Profit margin: 50% (up from 43% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 30
Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021) Second quarter 2022 results: EPS: CN¥1.34 (up from CN¥0.33 in 2Q 2021). Revenue: CN¥3.31b (up 190% from 2Q 2021). Net income: CN¥1.88b (up 300% from 2Q 2021). Profit margin: 57% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Board Change • May 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Non-Independent Director Dianhan Wei was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 02
Upcoming dividend of CN¥1.11 per share Eligible shareholders must have bought the stock before 09 May 2022. Payment date: 09 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 6.2%. Within top quartile of Chinese dividend payers (2.3%). Higher than average of industry peers (0.8%). Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Non-Independent Director Dianhan Wei was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: CN¥2.58 (vs CN¥1.75 in FY 2020) Full year 2021 results: EPS: CN¥2.58 (up from CN¥1.75 in FY 2020). Revenue: CN¥7.66b (up 44% from FY 2020). Net income: CN¥3.62b (up 48% from FY 2020). Profit margin: 47% (up from 46% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥2.56 (up from CN¥1.75 in FY 2020). Revenue: CN¥7.63b (up 43% from FY 2020). Net income: CN¥3.59b (up 47% from FY 2020). Profit margin: 47% (up from 46% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 14%. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥19.15, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 46x in the Biotechs industry in China. Total returns to shareholders of 248% over the past three years. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.34b (up 297% from 1Q 2020). Net income: CN¥1.13b (up CN¥942.3m from 1Q 2020). Profit margin: 48% (up from 32% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 31
Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥5.35b (up 387% from FY 2019). Net income: CN¥2.43b (up CN¥2.34b from FY 2019). Profit margin: 46% (up from 8.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 10
New 90-day low: CN¥29.03 The company is down 11% from its price of CN¥32.74 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥35.55, the stock is trading at a trailing P/E ratio of 20.1x, down from the previous P/E ratio of 23.9x. This compares to an average P/E of 62x in the Biotechs industry in China. Total returns to shareholders over the past three years are 210%. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥42.15 The company is up 22% from its price of CN¥34.45 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥31.98 The company is down 4.0% from its price of CN¥33.36 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.